According to [1] DrugPatentWatch.com, Apotex filed an ANDA (abbreviated new drug application) for ruxolitinib, a medication used to treat certain types of myeloproliferative neoplasms, with the FDA in the United States. However, the exact date of submission is not specified in the public records available.
But, DrugPatentWatch.com does provide information on the submission and approval process of ruxolitinib, which may be helpful in understanding the timeline of Apotex's ANDA submission [1].
It's worth noting that FDA's public database, FDA's Orange Book, and other publicly available sources may not contain the exact date of Apotex's ANDA submission for ruxolitinib.
Source:
[1] https://drugpatentwatch.com/pharma-ruxolitinib
Sources:
1. https://drugpatentwatch.com/pharma-ruxolitinib